You, Qiancheng
Cheng, Anthony Youzhi
Gu, Xi
Harada, Bryan T. http://orcid.org/0000-0002-9683-782X
Yu, Miao
Wu, Tong http://orcid.org/0000-0001-9968-9909
Ren, Bing http://orcid.org/0000-0002-5435-1127
Ouyang, Zhengqing http://orcid.org/0000-0003-2842-8503
He, Chuan http://orcid.org/0000-0003-4319-7424
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (F32CA221007)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM124998)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1HG008935)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U54CA193419)
Article History
Received: 14 August 2019
Accepted: 14 July 2020
First Online: 24 August 2020
Competing interests
: C.H. is a scientific founder and a member of the scientific advisory board of Accent Therapeutics, Inc. and a shareholder of Epican Genetech. B.R. is a co-founder and a member of the scienceitific advisory board of Arima Genomics Inc.